NCT04830813 - Phase 3 Clinical Study of Chiauranib Capsule in Patients With Small-cell Lung Cancer | Biotech Hunter

Enrollment

184

Participants

Timeline

Start Date

March 5, 2021

Primary Completion Date

April 1, 2024

Study Completion Date

April 1, 2024

Conditions

Small Cell Lung Cancer

Interventions

DRUG

Chiauranib

Patients take Chiauranib capsules 50mg, orally once daily, 21 days as a cycle until objective disease progression.

DRUG

Placebo

Participants received Chiauranib placebo capsule matching Chiauranib orally once daily until objective disease progression.

Trial Locations (1)

Cancer Hospital, Chinese Academy of Medical Sciences, Beijing